BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib
Isabella Faraoni(University of Rome Tor Vergata), Francesco Lo‐Coco(University of Rome Tor Vergata)
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
December 5, 2014
Cited by 62
Related Papers
High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts <i>in vitro</i>
|Oncotarget|2017|54
PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity
|Oncotarget|2016|26
Poly(ADP-Ribose) Polymerase Inhibitors for Arsenic Trioxide–Resistant Acute Promyelocytic Leukemia: Synergistic In Vitro Antitumor Effects with Hypomethylating Agents or High-Dose Vitamin C
|Journal of Pharmacology and Experimental Therapeutics|2021|10